September 23, 2016
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Five important updates in prostate cancer
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
National Prostate Cancer Awareness Month, observed in September, is intended to educate men about disease risk factors, screening options and other matters related to prostate health.
In conjunction with this observation, HemOnc Today presents five updates in prostate cancer research that may be relevant to your practice.
- Men who underwent vasectomy did not demonstrate elevated risk for prostate cancer incidence or mortality, according to an analysis of large prospective cohorts published in Journal of Clinical Oncology. Read more.
- Active monitoring appeared associated with a disease-specific mortality rate comparable to surgery and radiotherapy among men with localized prostate cancer. Read more.
- A greater number of docetaxel cycles extended OS in men with metastatic castration-resistant prostate cancer, according to a post-hoc analysis of the phase 3 Mainsail trial. Read more.
- The addition of prostate radiotherapy to androgen deprivation may prolong survival in men with newly diagnosed metastatic prostate cancer, according to a study published in Journal of Clinical Oncology. Read more.
- Radiotherapy and radical prostatectomy conferred equivalent survival outcomes among men with aggressive prostate cancer, according to the results of a comparative analysis. Read more.